文献速递泌尿男性生殖肿瘤

阿比特龙联合糖皮质激素方案治疗mCRPC的安全性评估:随机开放标签2期研究

Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer: A Randomized, Open-label Phase 2 Study.
PubMed 文献 · JAMA Oncol · 2019-01-01

该随机开放标签2期研究纳入164例mCRPC男性,比较阿比特龙联合四种糖皮质激素方案(泼尼松5mg每日两次、每日一次、2.5mg每日两次或地塞米松0.5mg每日一次)的安全性。主要终点为24周内无盐皮质激素过多(≥1级低钾血症或≥2级高血压)。结果显示泼尼松5mg每日两次和地塞米松0.5mg每日一次达到预设阈值,而泼尼松5mg每日一次和2.5mg每日两次未达到;地塞米松方案影像学无进展生存期较长但可能伴随代谢不良反应。

要点

  • 泼尼松5mg每日两次或地塞米松0.5mg每日一次联合阿比特龙达到主要终点预设阈值。
  • 泼尼松5mg每日一次或2.5mg每日两次联合阿比特龙未达到主要终点阈值。
  • 地塞米松方案影像学无进展生存期较长,但可能伴随代谢不良反应。

核心结论

  • 阿比特龙联合泼尼松5mg每日两次或地塞米松0.5mg每日一次达到主要终点预设阈值(95%CI排除50%盐皮质激素过多)。
  • 阿比特龙联合泼尼松5mg每日一次或2.5mg每日两次未达到主要终点阈值。
  • 阿比特龙联合地塞米松似乎特别有效,但可能与不良代谢后果相关。

研究设计与样本

  • 开放标签、随机(1:1:1:1)2期临床试验,纳入164例来自5个国家22家医院的mCRPC男性,2013年6月至2014年10月随机分配。
  • 干预为阿比特龙1000mg每日一次联合泼尼松5mg每日两次(n=41)、5mg每日一次(n=41)、2.5mg每日两次(n=40)或地塞米松0.5mg每日一次(n=42)。
  • 主要终点为治疗开始至24周(6周期)内无盐皮质激素过多(≥1级低钾血症或≥2级高血压)。

主要发现

  • 泼尼松5mg每日两次组34例中24例(70.6%,95%CI 53.8%-83.2%)无盐皮质激素过多。
  • 泼尼松5mg每日一次组38例中14例(36.8%,95%CI 23.4%-52.7%)无盐皮质激素过多。
  • 泼尼松2.5mg每日两次组35例中21例(60.0%,95%CI 43.6%-74.4%)无盐皮质激素过多。
  • 地塞米松0.5mg每日一次组37例中26例(70.3%,95%CI 54.2%-82.5%)无盐皮质激素过多。
  • 8周后泼尼松2.5mg每日两次和5mg每日一次组的血浆促肾上腺皮质激素和尿盐皮质激素代谢物高于泼尼松5mg每日两次或地塞米松0.5mg每日一次组;未达到主要终点者尿糖皮质激素代谢物水平似乎更高, regardless of glucocorticoid regimen。

关键数值与推荐

  • 主要终点预设阈值为95%CI排除50%盐皮质激素过多。
  • 泼尼松5mg每日两次组无盐皮质激素过多比例70.6%(95%CI 53.8%-83.2%),达到阈值。
  • 泼尼松5mg每日一次组无盐皮质激素过多比例36.8%(95%CI 23.4%-52.7%),未达到阈值。
  • 泼尼松2.5mg每日两次组无盐皮质激素过多比例60.0%(95%CI 43.6%-74.4%),未达到阈值。
  • 地塞米松0.5mg每日一次组无盐皮质激素过多比例70.3%(95%CI 54.2%-82.5%),达到阈值。

临床怎么用

  • 对于mCRPC患者,阿比特龙联合泼尼松5mg每日两次或地塞米松0.5mg每日一次可能更符合主要终点阈值。
  • 阿比特龙联合地塞米松影像学无进展生存期较长,但需监测代谢不良反应。
  • 不推荐阿比特龙联合泼尼松5mg每日一次或2.5mg每日两次作为达到主要终点阈值的方案。

局限性

  • 本研究为2期开放标签试验,样本量较小(共164例)。
  • 研究仅纳入mCRPC男性,结果可能不适用于其他人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Abiraterone acetate is combined with prednisone, 5 mg, twice daily for metastatic castration-resistant prostate cancer (mCRPC) and with prednisone, 5 mg, once daily for newly diagnosed, high-risk, metastatic castration-sensitive prostate cancer. Understanding the physiological effects of these and other regimens is important. OBJECTIVE: To evaluate the safety of abiraterone acetate with 4 glucocorticoid regimens. DESIGN, SETTING, AND PARTICIPANTS: Open-label, randomized clinical trial (1:1:1:1) of 164 men with mCRPC from 22 hospitals in 5 countries who were randomly assigned to 1 of 4 intervention groups between June 2013 and October 2014. Analyses were conducted from August 2017 to June 2018. INTERVENTIONS: Abiraterone acetate, 1000 mg, once daily with prednisone, 5 mg, twice daily (n = 41), 5 mg once daily (n = 41), 2.5 mg twice daily (n = 40), or dexamethasone, 0.5 mg, once daily (n = 42). MAIN OUTCOMES AND MEASURES: Primary end point was no mineralocorticoid excess (grade ≥1 hypokalemia or grade ≥2 hypertension) through 24 weeks (6 cycles) from treatment. RESULTS: Of 164 men (median [range] age, 70 [50-90] years) randomized to receive abiraterone acetate, 1000 mg, daily with prednisone, 5 mg, twice daily, once daily, or 2.5 mg twice daily, or dexamethasone, 0.5 mg, once daily, 24 (70.6%) of 34 patients (95% CI, 53.8%-83.2%), 14 (36.8%) of 38 patients (95% CI, 23.4%-52.7%), 21 (60.0%) of 35 patients (95% CI, 43.6%-74.4%), and 26 (70.3%) of 37 patients (95% CI, 54.2%-82.5%), respectively, had no mineralocorticoid excess. Plasma adrenocorticotrophic hormone and urinary mineralocorticoid metabolites after 8 weeks were higher with prednisone, 2.5 mg, twice daily and 5 mg once daily than with 5 mg twice daily or dexamethasone, 0.5 mg, once daily. The level of urinary glucocorticoid metabolites appeared higher in patients who did not meet the primary end point, regardless of glucocorticoid regimen. Total lean body mass decreased in the prednisone groups and total body fat increased in the prednisone, 5 mg, twice daily and dexamethasone groups. In the dexamethasone group, there was an increase in serum insulin and homeostatic model assessment of insulin resistance, while total bone mineral density decreased. In the prednisone, 5 mg, twice daily, 5 mg once daily, 2.5 mg twice daily, and dexamethasone groups, median radiographic progression-free survival was 18.5, 15.3, 12.8, and 26.6 months, respectively. CONCLUSIONS AND RELEVANCE: Abiraterone acetate with prednisone, 5 mg, twice daily or dexamethasone, 0.5 mg, once daily met the prespecified threshold for the primary end point (95% CI excluded 50% mineralocorticoid excess); abiraterone acetate with prednisone, 5 mg, once daily or 2.5 mg twice daily did not meet the threshold. Abiraterone acetate in combination with dexamethasone appeared to be particularly active but may be associated with adverse metabolic consequences. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01867710.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Attard G, Merseburger AS, Arlt W, et al. Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer: A Randomized, Open-label Phase 2 Study. JAMA Oncol. 2019. PMID: 31246234. doi:10.1001/jamaoncol.2019.1011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。